Discovery of a novel simian pegivirus in common marmosets (*Callithrix jacchus*) with lymphocytic enterocolitis

Anna S. Heffron[1], Michael Lauck [1], Elizabeth D. Somsen[1], Elizabeth C. Townsend[1], Adam L. Bailey[2], Megan Sosa[3], Jens Eickhoff[4], Saverio Capuano III[3], Christina M. Newman[1], Jens H. Kuhn[5], Andres Mejia[3], Heather A. Simmons[3], David H. O'Connor[1,3]

Affiliations

[1] Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

[2] Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America

[3] Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

[4] Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison, Madison, WI, United States of America

[5] Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, United States of America

Abstract

From 2010 to 2015, 73 common marmosets (*Callithrix jacchus*) housed at the Wisconsin National Primate Research Center (WNPRC) were diagnosed postmortem with lymphocytic enterocolitis. We used unbiased deep-sequencing to screen the blood of deceased enterocolitis-positive marmosets for the presence of RNA viruses. In five out of eight marmosets with lymphocytic enterocolitis, we discovered a novel pegivirus that was not present in ten subsequently deep-sequenced matched, clinically-normal common marmosets with no evidence of lymphocytic enterocolitis. The novel virus, which we have named Southwest bike trail virus (SOBV), is most closely related (68% nucleotide identity) to a strain of simian pegivirus A that was previously isolated from a three-striped night monkey (*Aotus trivirgatus*). To determine the prevalence of this novel virus within the WNPRC marmoset colony, we screened 146 living animals and found an overall prevalence of 34% (50/146). Over the next four years, 85 of the 146 screened marmosets died or were euthanized and were examined histologically for lymphocytic enterocolitis. Out of these 85 animals, 27 SOBV-positive common marmosets had developed lymphocytic enterocolitis, compared to 42 SOBV-negative common marmosets, indicating no evidence of an association between this virus and development of enterocolitis in this cohort (*p*=0.0798). The novel pegivirus was also found in two of 32 (6%) clinically-normal common marmosets screened while in quarantine during the transfer from the New England Primate Research Center to the WNPRC, suggesting SOBV has different prevalence at different

39 centers and could exert confounding influences on the comparison of marmoset studies from
40 multiple centers.

Importance

Common marmosets (*Callithrix jacchus*) are a valuable model species. We discovered two
variants of a novel simian pegivirus, which we named the Southwest bike trail virus (SOBV), in
common marmosets which had postmortem histologic diagnosis of lymphocytic enterocolitis.
The virus was not present in ten matched, clinically-normal controls. We screened 146 live
healthy common marmosets in the Wisconsin National Primate Research Center colony and
found 34% (50/146) of the animals were SOBV-positive. SOBV was also present in two of 32
(6%) clinically-normal common marmosets from the New England Primate Research Center.
These findings could have confounding effects in animal studies, especially those in which
infection-free animals are desired, and they demonstrate the need for further investigations into
SOBV transmission, the length of time of SOBV persistence, and SOBV prevalence at other
primate centers, in order to increase understanding of the effects of SOBV and of this viral
genus.

Introduction

Common marmosets (*Callithrix jacchus*) are a valuable model species due to their small body
size, communal monogamous familial behavior, birth of hematopoietic chimeric litters, short
parturition intervals, and status as members of a non-endangered primate species.[1-5] The utility
of common marmosets in research has resulted in a recent increase in demand for these
animals.[6] The Wisconsin National Primate Research Center (WNPRC) in Madison, Wisconsin,
USA, houses a common marmoset colony typically consisting of about 240 common
marmosets, which are used by researchers at the University of Wisconsin-Madison for
groundbreaking research in neurological, neurobehavioral, and pharmacologic research, among
many others.[7-17]
64
From 2010 to 2015, 73 common marmosets housed at the WNPRC were euthanized due
experimental end point, chronic intractable diarrhea, or chronic severe weight loss, underwent
necropsy with histology, and were diagnosed with lymphocytic enterocolitis.[18-21] Beyond the
regrettable loss of animal life, common marmoset morbidity and mortality due to enterocolitis is
harmful both to colony success and to the scientific studies to which these animals are
assigned. Though lymphocytic enterocolitis is one of the most common causes of death in
captive common marmosets,[18-23] the epizootic at the WNPRC was associated with an unusually
high disease incidence for the colony, prompting investigations into a possible infectious
contributor. Unbiased deep-sequencing led to the discovery of two similar variants of a novel
pegivirus, most closely related to a variant of simian pegivirus A (SPgV-A) previously isolated
from a three-striped night monkey (*Aotus trivirgatus*). This novel pegivirus was present in a
subset of deceased common marmosets diagnosed postmortem with lymphocytic enterocolitis
and was not present in matched, clinically-normal controls.
78
Pegiviruses, members of genus *Pegivirus (Amarillovirales*: *Flaviviridae)*, are ubiquitous in
animal populations,[24-35] but their biological consequences are poorly understood. Pegiviruses
can persist at high titers for years or decades in humans[36-40] and chimpanzees[41] with an
unusually low mutation rate compared to other RNA viruses,[38,42] and they have never been
shown to be the causative agent of any disease.[43-60] Apparent links between pegiviruses and
disease, such as that initially posited for Theiler's disease associated virus (TDAV) and Theiler's

disease,[61,62] have later been shown to be more likely spurious.[35,63] The mechanisms of pegivirus
biology have eluded definition, but these viruses are considered most likely lymphotropic,[64-67]
and evidence from *in vivo* and *in vitro* studies suggests they may affect T cell functioning and
homeostasis.[68-76] Lymphocytic enterocolitis in common marmosets is likewise characterized by
a dysregulation of T cell biology, as the intestinal villus architecture is disrupted or lost due to
the intraepithelial infiltration of large numbers of CD3 CD8-positive lymphocytes.[22] Given the
importance of common marmosets as a model species and the disease burden caused by
lymphocytic enterocolitis, we set out to characterize the possible link between this new virus and
the disease state.
94
Here, we report the discovery of two variants of a novel pegivirus in a captive common
marmoset colony. We establish phylogenetic relationships with other known pegiviruses. Since
this virus was discovered in common marmosets with lymphocytic enterocolitis and was absent
in clinically-normal controls, we measure the prevalence of the virus in the colony and track the
potential association of viral status with risk of developing lymphocytic enterocolitis disease over
four years. Our findings have implications for animal studies in which specific pathogen-free
animals are desired, and they demonstrate the need for further investigations to increase
understanding of these viruses and their impact on common marmoset health.

103   Results

104   Captive common marmosets harbor a novel pegivirus

To examine the etiology of the unusually high rate of lymphocytic enterocolitis in deceased
WNPRC common marmosets, banked plasma samples from eight common marmosets
diagnosed with lymphocytic enterocolitis and from ten clinically-normal, live common marmosets
to be used as controls were screened by deep sequencing for the presence of viral RNA. RNA
from a previously undocumented pegivirus was detected in the plasma of five of eight deceased
marmosets with lymphocytic enterocolitis. We propose this novel virus (BioProject
PRJNA613737) be formally named the Southwest bike trail virus (SOBV). Pegivirus RNA was
not detected in the plasma of the ten clinically-normal common marmoset controls.
113
SOBV consists of a 9.8-kb-long contig that is highly similar to the genome of simian pegivirus A
(SPgV A) trivirgatus, a simian pegivirus previously discovered in a three-striped night monkey
(*Aotus trivirgatus*)[27] (Figure 1), with 68% nucleotide identity across the coding sequence when
aligned using ClustalW with an IUB cost matrix (gap extension cost, 6.66; gap open cost,
15.00). Four of the five common marmosets positive for SOBV had variants of the virus having
98-99% sequence identity, while one common marmoset had a variant with 88% sequence
identity to the others. We have named these variants SOBV-1 (GenBank accession number
MT513216) and SOBV-2 (GenBank accession number MT513217).
122
123 Pairwise comparisons of nucleotide identity across the entire coding region further illustrate the
124 similarity of SOBV-1 and SOBV-2 and the divergence between these novel virus strains and the
125 next most closely-related viruses (Figure 2, Figure 3), most of which were simian pegiviruses.
126 Several pegivirus isolates found in a bat[77] also shared high degrees of similarity with the novel
127 pegivirus.
128

Figure 1. A phylogenetic tree of newly discovered pegivirus Southwest bike trail virus (SOBV
variants 1 and 2) shows it is most closely related to pegiviruses found in other New World
monkeys and bats. We generated maximum likelihood trees using MEGA6.06 (1,000 bootstrap
replicates, GTR+I+γ model) from codon-based alignments (via MAFFT); Bootstrap values of
less than 70 are omitted.
Abbreviations: HPgV = human pegivirus; SPgV = simian pegivirus

137
Figure 2. Sliding window similarity plots[78] show the relatedness of the amino acid sequences of
SOBV-2 and other closely related pegiviruses to SOBV-1. Dashed vertical lines indicate the
putative approximate start positions of inferred viral proteins, from left to right: E1, E2, P7, NS2,
NS3, NS4A, NS4B, NS5A, and NS5B.[79]
Abbreviations: SPgV-A nigri = GBV-A-like virus recovered from *Saguinus nigricollis*; SPgV-A tri
= GBV-A-like virus recovered from *Aotus trivirgatus*; SPgV-A mx = GBV-A-like virus recovered
from *Saguinus mystax*; SPgV-A lab = GBV-A-like virus recovered from *Saguinus labiatus*; BPgV
737 = bat pegivirus recovered from *Eidolon helvum*

147
148 **Figure 3.** Sequence identity matrix based on amino acid alignment of the newly discovered
149 SOBV-1 and SOBV-2 (red box) compared to members of the 11 recognized pegivirus species
150 and of one* proposed species.[79]
151 *The classification of dolphin into species "Pegivirus L" has been suggested.[80]

Novel pegivirus RNA is detected in up to 34% of a captive common marmoset colony

Having identified the novel pegivirus in diseased animals, we sought to determine its prevalence within the WNPRC common marmoset colony. We developed an RT-PCR assay to detect a conserved region of the putative helicase protein of SOBV and used this to screen plasma collected from 146 clinically-normal live common marmosets in the WNPRC colony, confirming results through deep-sequencing of the amplicons. At the time of the initial screening in March–April 2014, 50 of the 146 (34.25%) clinically-normal screened animals tested positive for SOBV RNA. Nineteen of 60 females (31.67%) and 31 of 86 males (36.05%) tested positive at the time of screening. Sex was not associated with the likelihood of SOBV using univariate logistic regression (p=0.583). Age at the time of screening was associated with the likelihood of SOBV (p=0.0324), with the likelihood of positivity increasing with age (Figure 4).

WNPRC common marmosets screened for SOBV			
Age (years) at time of screening	Total number common marmosets	Number common marmosets infected	Number common marmosets non-infected
1	20	6	14
2	24	5	19
3	18	6	12
4	14	3	11
5	22	8	14
6	7	2	5
7	14	9	5
8	13	3	10
9	5	4	1
10	6	2	4
11	2	1	1
12	0	0	0
13	1	1	0

Figure 4. Prevalence of infection with Southwest bike trail virus (SOBV) in common marmosets at the WNPRC increases with age. One hundred forty-six live, clinically-normal common marmosets in the WNPRC captive common marmoset colony were screened for SOBV using RT-PCR and deep sequencing methods. The likelihood of infection with these viruses was significantly statistically associated with increasing age (p=0.03237) using univariate logistic regression.

In November 2014, 82 common marmosets were transferred from the New England Primate Research Center (NEPRC) to the WNPRC. Samples from 32 NEPRC common marmosets were collected while the animals were in quarantine. Two (6%) of these were found to be positive for SOBV RNA when screened by RT-PCR.

Presence of novel pegivirus is not statistically significantly associated with lymphocytic enterocolitis in the common marmoset

Given that pegiviruses are known to persist in hosts for years or decades,[36-41] we sought to determine whether SOBV-positive animals were more likely to develop lymphocytic enterocolitis over a period of observation. Typical enteric architecture consists of slender, often branching villi, with short intestinal glands, small numbers of lymphocytes in the lamina propria, and prominent B cell aggregates dispersed throughout the length of the intestines (Figure 5, control).

Lymphocytic enterocolitis was diagnosed as a disruption of this architecture, with lymphocytic infiltration that expands the lamina propria, resulting in widening and shortening of villi and hyperplasia of crypt epithelium (Figure 5, E1-E3). Cases varied in severity, with mild cases showing only slight expansion of the lamina propria and advanced cases showing complete loss of villus architecture due to infiltration of the lamina propria with large numbers of CD3-positive lymphocytes. Eighty-five of the live WNPRC animals initially screened for SOBV in 2014 were euthanized for experimental end points or clinical illness between their screening and May 3, 2019. Sixty-nine (81.18%) of these animals were diagnosed by postmortem histological analysis with lymphocytic enteritis, colitis, or enterocolitis. Two animals were removed from this analysis due to confounding factors (one animal had severe tissue autolysis, and the other animal had B cell lymphoma of the small and large intestines).

duodenum

jejunum   control

colon

duodenum

jejunum   E1

colon

duodenum

jejunum   E2

colon

duodenum

jejunum   E3

colon

4x   10x   CD20   CD3

H&E   IHC (4x)

Figure 5. Representative photomicrographs show disruption of the normal architecture in the
duodenum, jejunum, and colon by lymphocytic enterocolitis in common marmosets. Histology
was performed upon intestinal samples from 85 common marmosets. Intestinal sections were
stained with hematoxylin and eosin (H&E) and with B cell-specific and T cell-specific staining
procedures (immunohistochemistry) with monoclonal antibodies to CD20 or CD79 (B cell
markers) and CD3 (T cell marker), respectively.
207
208 Pegivirus infection was not found to be associated with an increased likelihood of developing
209 lymphocytic enteritis in the small intestines (*p*=0.779), colitis in the large intestine (*p*=0.196),
210 either a colitis or enteritis (*p*=0.820), or an enterocolitis (*p*=0.0798), or with lack of any
211 lymphocytic disease (*p*=0.904) (Figure 6). Sex was not associated with likelihood of the various
212 disease states (*p*=0.400, *p*=0.912, *p*=0.235, *p*=0.812, and *p*=0.235, respectively).
213

214
Figure 6. Infection with Southwest bike trail virus (SOBV) is not associated with the likelihood of
developing lymphocytic enteritis, colitis, or enterocolitis. Eighty-five common marmosets at the
WNPRC, which had been previously screened for SOBV by RT-PCR or deep-sequencing of
plasma samples, were examined postmortem for histological evidence of lymphocytic
enterocolitis. Pegivirus infection was not found to be associated with an increased likelihood of
developing lymphocytic colitis (*p*=0.196), enteritis (*p*=0.779), either enteritis or colitis (*p*=0.820),
enterocolitis (*p*=0.0798), or lack of lymphocytic disease (*p*=0.904), using univariate logistic
regression.

Discussion

We describe the discovery of a novel simian pegivirus, the Southwest bike trail virus (SOBV),
first identified in common marmosets diagnosed with lymphocytic enterocolitis. We show this
pegivirus was prevalent in our colony during a period of increased incidence of lymphocytic
enterocolitis and that it was less prevalent in a similar, clinically-normal colony. The novel virus
was not significantly associated with the likelihood of developing lymphocytic enterocolitis,
though prevalence of the virus increased with increasing age in the common marmoset. With an

average prevalence of 34%, SOBV is common throughout the WNPRC common marmoset
colony.
232
Pegiviruses, the members of genus *Pegivirus (Amarillovirales: Flaviviridae)*, have single-
stranded, positive-sense RNA genomes and produce enveloped virions.[81] The first members of
the genus were identified about 20 years ago,[82,83] and since that time pegiviruses have been
found in many animal populations.[24-35,80] Pegiviruses have never been shown to be causative
agents of any disease or alteration in physiology.[43-60] Human pegivirus (HPgV) has been linked
both to improved outcomes in HIV-1 infection[68,84-101] and to increased incidence of various types
of lymphoma,[102-110] though this remains controversial.[111-115] HPgV is considered likely
lymphotropic,[64-67] and evidence from *in vivo* and *in vitro* research suggests HPgV may affect T
cell activation, signaling, proliferation and apoptosis, and CD4 or CD8 expresssion,[68-76] and that
it may be associated with a higher rate of host cell DNA damage[116] and genomic
destabilization.[107] These effects on T cell functions may be a common pathway through which
these viruses may cause lymphocytic diseases.
245
It is not known whether common marmosets are the natural host for SOBV or whether they
acquired this virus from another species in captivity.[117] Other pegiviruses have been discovered
in wild common marmosets in the 1990s,[118] but their prevalence has never been examined. The
prevalence of SOBV in our captive common marmoset population was quite high compared to
the prevalence of HPgV, which is found in about 1–4% of human populations,[119-126] and
compared to the prevalence of pegiviruses in captive chimpanzees (1-3%).[41] SOBV is most
similar to a pegivirus discovered in a three-striped night monkey (*Aotus trivirgatus*),[27] a species
used in malaria research at other primate research facilities,[127-129] indicating SOBV may have
been introduced into common marmosets through contact in captivity. Interestingly, SOBV is
highly similar to several variants of a bat pegivirus isolated from African straw-colored fruit bats
(*Eidolon helvum*). Given that common marmosets and three-striped night monkeys are native to
northern South America, this may indicate a South American bat species harbors a more
closely-related pegivirus and could have been the source of an interspecies spillover.
259
The routes of transmission of SOBV and of other simian pegiviruses have not been examined.
Human pegivirus transmission has been extensively studied and is known to occur efficiently
through blood products or dialysis,[36,45,130-133] intravenous drug use and needle sticks,[130,134-136]
sexual intercourse,[130,134,137,138] and from mother to infant.[130,139-143] Captive common marmosets
are typically housed in familial groups in shared cages and receive some vaccines and other
medication by injection, and common marmosets frequently give birth to non-identical twins.[3-5,22]
These animals thus have the potential to transmit SOBV through direct contact, sexual contact,
birth, and medical injections or veterinarian manipulations. Defining mechanisms of
transmission will be important in preventing infection and thereby allowing the study of this virus'
effects.
270
The high prevalence of this virus at the WNPRC raises important considerations about potential
effects on common marmoset experiments. Facilities working with common marmosets should
prescreen the animals to establish the pegivirus status of animals in research to account for
potential confounding. Pegiviruses can replicate at high titers in a host for more than a
decade;[36,37,41,144] thus, the length of time for which an animal has been continuously infected
may also be relevant in potentially confounding study outcomes. Future investigations, perhaps
involving the isolation of common marmosets for years at a time to follow the natural history of
chronic pegivirus infection in these animals, could examine the long-term effects of infecting
common marmosets with SOBV.
280

This study has several limitations. First, this study was observational in nature, as we did not want to risk infecting more marmosets in our research colony with an apparently transmissible and potentially harmful virus. This study design could not examine a causal link between viral positivity and the development of lymphocytic enterocolitis. Definitive establishment of causation would require demonstrating that animals infected experimentally develop the disease. Second, many animals in this study were concurrently enrolled in other WNPRC studies, and therefore some were euthanized earlier than would have occurred otherwise when those studies reached experimental endpoints. We chose to use this convenience sample as it allowed us to achieve a large study sample size in which to investigate a potential infectious contributor to an important and poorly-understood cause of common marmoset mortality without disrupting other ongoing studies at the WNPRC. Third, not all of the animals initially screened were deceased at the time of this analysis, and future necropsies of these animals may contribute additional data concerning the likelihood of enterocolitis development. Finally, some animals in this study may have cleared the virus before the samples we tested were collected. Consequently, these animals could have been mistakenly classified as virus-naïve; others may have acquired the virus after our initial screening. Development of a SOBV-specific ELISA or other serodiagnosis tools would enable deeper appropriate analyses of SOBV infection rates both prospectively and retrospectively.

In summary, this work describes the discovery of a novel simian pegivirus and investigates its relationship with a widespread and devastating cause of common marmoset mortality. Our study lays the groundwork for the future development of a nonhuman primate model system using this natural infection as a potential model for studying the mechanisms of these enigmatic viruses and providing a greater understanding of their genus as a whole.

Materials and methods

Animals

All animals in this study were common marmosets (*Callithrix jacchus* Linnaeus, 1758) housed at the Wisconsin National Primate Research Center (WNPRC) in Madison, WI, USA. The common marmoset colony at the WNPRC was established in 1960. The original animals were imported from northeastern Brazil, with the final importation occurring in the early 1970s. The average yearly population of the colony each year from 2010 to 2019 was approximately 240 animals, all of which were born in captivity. WNPRC animals screened were 41% (60 animals) female and 59% (86 animals) male. Age at the time of screening ranged from 0.82–12.82 years (mean 4.65+/-2.83 years, median 4.26 years).

The New England Primate Research Center (NEPRC), Southborough, MA, USA, was closed in 2015, resulting in a transfer of 82 common marmosets to WNPRC before closure in November 2014. Plasma samples were collected from some of these animals upon their arrival at WNPRC (November–December 2014) while quarantined in a separate building and location from the WNPRC marmoset colony. In the population initially from the NEPRC, 45 (55%) of the screened animals were female, and 37 (45%) were male. Age at the time of screening ranged from 0.65–10.66 years (mean 3.74+/-2.60, median 2.51 years) in this population.

Ethics

324
All common marmosets were cared for by WNPRC staff according to the regulations and
guidelines outlined in the National Research Council's Guide for the Care and Use of Laboratory
Animals, the Animal Welfare Act, the Public Health Service Policy on the Humane Care and Use
of Laboratory Animals, and the recommendations of the Weatherall report
(https://royalsociety.org/topics-policy/publications/2006/weatherall-report/). Per WNPRC
standard operating procedures for animals assigned to protocols involving the experimental
inoculation of infectious pathogens, environmental enhancement included constant visual,
auditory, and olfactory contact with conspecifics, the provision of feeding devices that inspire
foraging behavior, the provision and rotation of novel manipulanda, and enclosure furniture (i.e.,
perches, shelves). The common marmosets were housed socially in enclosures measuring
0.6m D × 0.9m W × 1.8 m H or 0.6m D × 1.2m W × 1.8 m H. The WNPRC maintains an
exemption from the USDA for these enclosures as they do not meet the Animal Welfare Act
regulations for floor space but greatly exceed height requirements as the species are arboreal.
This study was approved by the University of Wisconsin-Madison College of Letters and
Sciences and Vice Chancellor for Research and Graduate Education Centers Institutional
Animal Care and Use Committee (animal protocol numbers G005401 and G005443).

Unbiased deep-sequencing

Samples from 18 common marmosets (8 deceased common marmosets diagnosed with
lymphocytic enterocolitis through necropsy and 10 live, healthy common marmosets) from the
WNPRC and 12 common marmosets (all live and healthy) from the NEPRC were screened for
the presence of viruses using unbiased deep-sequencing. The live WNPRC common
marmosets and the live NEPRC common marmosets were selected randomly for deep-
sequencing.
348
DNA and RNA were isolated from plasma. Common marmoset plasma (1 ml/animal) was
centrifuged at 5,000 x *g* for 5 min at 4°C. Supernatants were removed and filtered through a
0.45-µm filter, then centrifuged at maximum speed (20,817 g) for 5 min at 4°C. Supernatants
were removed and incubated for 90 min at 37°C with a DNA/RNA digest cocktail consisting of 4
µl DNAfree DNAse (0.04 U/µl; Ambion, Austin, TX, USA), 6 µl Baseline Zero DNAse (0.1 U/µl,
Epicentre Technologies, Madison, WI, USA), 1 µl Benzonase (1 U/µl, Sigma-Adrich, St. Louis,
MO, USA), and 12 µl DNAse 10x buffer. Viral nucleic acids were then isolated using the Qiagen
QIAamp MinElute Virus Spin Kit without the use of AW1 buffer or carrier RNA (Qiagen,
Valencia, CA, USA). Random hexamers were used to prime cDNA synthesis (Life
Technologies, Grand Island, NY, USA), followed by DNA purification using Ampure XP beads,
as previously described.[145,146] Deep-sequencing libraries were prepared using the Nextera XT
DNA Library Prep Kit (Illumina, San Diego, CA, USA) and sequenced on MiSeq (Illumina).

Viral sequence and phylogenetic analysis

Sequence data were analyzed using CLC Genomics Workbench 5.5 (CLC bio, Aarhus,
Denmark). Low-quality reads (Phred <Q30) and short reads (<100 bp) were removed with CLC
Genomics Workbench 7.1 (CLC bio, Aarhus, Denmark), and the remaining reads were
assembled *de novo* using the MEGAHIT assembler. Assembled contiguous sequences
(contigs) and singleton reads were queried against GenBank database nt using the basic local
alignment search tools blastn. Nucleotide sequences were codon aligned individually for all
known pegiviruses with complete genomes using ClustalW in the alignment editor program in

MEGA6.06 and edited manually. The best-fitting distance model of nucleotide substitution for
each alignment was inferred using the maximum likelihood (ML) method with goodness of fit
measured by the Bayesian information criterion in MEGA6.06. The best-fitting nucleotide
substitution model for the phylogenetic alignments was inferred to be the GTR model with
discrete gamma and invariant among-site rate variation.
374
375 Protein family analysis and putative protein predictions were performed using Pfam
376 (http://pfam.xfam.org/). The nucleotide similarity of the novel pegivirus with related pegivirus
377 lineages was determined across the polyprotein using SimPlot v3.5.1[78] following TranslatorX
378 alignment (MAAFT) without Gblocks cleaning.
379
380 The sequence similarity matrix was created in Geneious Prime 2020.1.2 (Auckland, New
381 Zealand) using representative members of each pegivirus species.[79,80]

Screening for SOBV by RT-PCR

383 Plasma samples from 136 healthy WNPRC common marmosets were screened specifically for
384 SOBV by RT-PCR. Twenty plasma samples collected from NEPRC animals were likewise
385 screened by RT-PCR.
386
Screening of these animals was performed with samples from animals positive for SOBV by
deep-sequencing as positive controls. RNA was isolated from 100–500 µl of plasma using the
QIAamp Viral RNA Mini Kit (Qiagen). A primer set (forward primer:
GGTGGTCCACGAGTGATGA; reverse primer: AGGTACCGCCTGGGGTTAG) targeting a
region of the viral helicase which was conserved among the animals initially positive by deep
sequencing was designed, resulting in a 615-bp amplicon. Viral RNA was reverse-transcribed
and amplified using the SuperScript III High Fidelity One-Step RT-PCR kit (Invitrogen, Life
Technologies, Carlsbad, CA, USA). The reverse transcription-PCR conditions were as follows:
50°C for 30 min; 94°C for 2 min; 40 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 1 min;
and 68°C for 5 min. Following PCR, amplicons were purified from excised gel slices (1%
agarose) using the Qiagen MinElute Gel Extraction kit (Qiagen). Each amplicon was quantified
using Quant-IT HS reagents (Invitrogen), and approximately 1 ng of each was used in a
tagmentation reaction with the Nextera XT DNA Library Prep Kit. Final libraries representing
each amplicon were characterized for average length using a DNA high sensitivity chip on a
2100 bioanalyzer (Agilent Technologies, Loveland, CO, USA) and quantitated with Quant-IT HS
reagents. Libraries were sequenced on a MiSeq.

Postmortem diagnosis of lymphocytic enterocolitis

All animals humanely euthanized or found dead at the WNPRC undergo complete post mortem
examination (necropsy) with histology. Standard hematoxylin and eosin (H&E) stains are used
for histological examinations to determine whether normal tissue architecture and cellular
populations are present. In this study, immunohistochemical (IHC) CD3 and CD20 or CD79
staining was additionally performed on samples from these animals to differentiate lymphocyte
populations (primarily T cells, B cells, or mixed T and B cells). Diagnosis of T-cell rich
lymphocytic enterocolitis was based on abnormal architecture of the intestines and IHC
staining.[22,147] If confounding factors hampered diagnosis (e.g., severe B cell lymphoma or
autolysis), the animal was removed from the analysis.

Statistical analysis

We used univariate logistic regression to evaluate the associations of SOBV viremia with enterocolitis risk. Analyses were repeated to determine association with lymphocytic disease in small intestines only, large intestines only, both the small and large intestines, and either the small or large intestines. All reported P-values are two-sided and $P<0.05$ was used to define statistical significance. Statistical analyses were conducted using R version 3.6.3 in RStudio version 1.1.383.

Data accessibility and management

Metagenomic sequencing data have been deposited in the Sequence Read Archive (SRA) under Bioproject PRJNA613737. Derived data, analysis pipelines, and figures have been made available for easy replication of these results at a publicly-accessible GitHub (https://github.com/aheffron/SPgVwnprc_in_marmosets).

Acknowledgments

This work was supported in part through Laulima Government Solutions, LLC prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272201800013C. J.H.K. performed this work as employees of Tunnell Government Services (TGS), a subcontractor of Laulima Government Solutions, LLC under Contract No. HHSN272201800013C. The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. We would like to thank the WNPRC Animal Services, especially Christina Cruzen, Anna Goodroe, and Casey Fitz for medical care and sample collection from the live animals included in this study and the Pathology Services Unit including Dr. Daniel I. Schenkman and Dr. Raman Muthuswamy for necropsy and diagnostic services. Access to the dolphin silhouette was generously provided by Chris Huh (https://creativecommons.org/licenses/by-sa/3.0/). This research was supported by R01AI116382 (to D.H.O) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (www.niaid.nih.gov). This work was also supported in part by the Office of Research Infrastructure Programs/OD (P51OD011106) awarded to the Wisconsin National Primate Research Center at the University of Wisconsin - Madison. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program (https://orip.nih.gov/) grants RR15459-01 and RR020141-01. Author A.S.H has been supported by NRSA award T32 AI078985 and NRSA award T32 AI007414. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

References

1.   Tardif S, Bales K, Williams L, et al. Preparing New World monkeys for laboratory research. *ILAR J.* 2006;47(4):307-315.

2.   Abbott DH, Barnett DK, Colman RJ, Yamamoto ME, Schultz-Darken NJ. Aspects of
common marmoset basic biology and life history important for biomedical research.
Comp Med. 2003;53(4):339-350.
3.   Mansfield K. Marmoset models commonly used in biomedical research. *Comp Med.*
2003;53(4):383-392.
4.   Primate Factsheets: Common marmoset (Callithrix jacchus) Taxonomy, Morphology, &
Ecology. 2005. http://pin.primate.wisc.edu/factsheets/entry/common_marmoset.
Accessed 04 April 2020.
5.   Smucny DA, Abbott DH, Mansfield KG, et al. Reproductive output, maternal age, and
survivorship in captive common marmoset females (Callithrix jacchus). *Am J Primatol.*
2004;64(1):107-121.
6.   Servick K. Why are U.S. neuroscientists clamoring for marmosets? *Science Magazine.*
23 Oct. 2018, 2018.
7.   Converse AK, Aubert Y, Allers KA, Sommer B, Abbott DH. Flibanserin-Stimulated
Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets. *J Sex*
Med. 2015;12(12):2256-2266.
8.   Smith AL, Freeman SM, Barnhart TE, et al. Initial investigation of three selective and
potent small molecule oxytocin receptor PET ligands in New World monkeys. *Bioorg*
Med Chem Lett. 2016;26(14):3370-3375.
9.   Ausderau KK, Dammann C, McManus K, Schneider M, Emborg ME, Schultz-Darken N.
Cross-species comparison of behavioral neurodevelopmental milestones in the common
marmoset monkey and human child. *Dev Psychobiol.* 2017;59(7):807-821.
10.   Vermilyea SC, Guthrie S, Meyer M, et al. Induced Pluripotent Stem Cell-Derived
Dopaminergic Neurons from Adult Common Marmoset Fibroblasts. *Stem Cells Dev.*
2017;26(17):1225-1235.
11.   Olson EJ, Shaw GC, Hutchinson EK, et al. Bone Disease in the Common Marmoset:
Radiographic and Histological Findings. *Vet Pathol.* 2015;52(5):883-893.
12.   Ziegler TE, Sosa ME, Colman RJ. Fathering style influences health outcome in common
marmoset (Callithrix jacchus) offspring. *PLoS One.* 2017;12(9):e0185695.
13.   Kropp J, Di Marzo A, Golos T. Assisted reproductive technologies in the common
marmoset: an integral species for developing nonhuman primate models of human
diseases. *Biol Reprod.* 2017;96(2):277-287.
14.   Jones CA, Duffy MK, Hoffman SA, et al. Vocalization development in common
marmosets for neurodegenerative translational modeling. *Neurol Res.* 2018;40(4):303-
311.
15.   Iwatsuki-Horimoto K, Nakajima N, Kiso M, et al. The Marmoset as an Animal Model of
Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the
Conventional or Tracheal Spray Route. *Front Microbiol.* 2018;9:844.
16.   Braun K, Schultz-Darken N, Schneider M, Moore CF, Emborg ME. Development of a
novel postnatal neurobehavioral scale for evaluation of common marmoset monkeys.
Am J Primatol. 2015;77(4):401-417.
17.   Kraynak M, Flowers MT, Shapiro RA, Kapoor A, Levine JE, Abbott DH. Extraovarian
gonadotropin negative feedback revealed by aromatase inhibition in female marmoset
monkeys. *Am J Physiol Endocrinol Metab.* 2017;313(5):E507-E514.
18.   Parambeth JC, Ross CN, Miller AD, et al. Serum Cobalamin and Folate Concentrations
in Common Marmosets (Callithrix jacchus) with Chronic Lymphocytic Enteritis. *Comp*
Med. 2019;69(2):135-143.
19.   Chalmers DT, Murgatroyd LB, Wadsworth PF. A survey of the pathology of marmosets
(Callithrix jacchus) derived from a marmoset breeding unit. *Lab Anim.* 1983;17(4):270-
279.

20. David JM, Dick EJ, Jr., Hubbard GB. Spontaneous pathology of the common marmoset
(Callithrix jacchus) and tamarins (Saguinus oedipus, Saguinus mystax). *J Med Primatol.*
2009;38(5):347-359.
21. Tucker MJ. A survey of the pathology of marmosets (Callithrix jacchus) under
experiment. *Lab Anim.* 1984;18(4):351-358.
22. Ludlage E, Mansfield K. Clinical care and diseases of the common marmoset (Callithrix
jacchus). *Comp Med.* 2003;53(4):369-382.
23. Kaspareit J, Friderichs-Gromoll S, Buse E, Habermann G. Background pathology of the
common marmoset (Callithrix jacchus) in toxicological studies. *Exp Toxicol Pathol.*
2006;57(5-6):405-410.
24. Bukh J, Kim JP, Govindarajan S, et al. Experimental infection of chimpanzees with
hepatitis G virus and genetic analysis of the virus. *J Infect Dis.* 1998;177(4):855-862.
25. Birkenmeyer LG, Desai SM, Muerhoff AS, et al. Isolation of a GB virus-related genome
from a chimpanzee. *J Med Virol.* 1998;56(1):44-51.
26. Cheng Y, Zhang W, Li J, et al. Serological and histological findings in infection and
transmission of GBV-C/HGV to macaques. *J Med Virol.* 2000;60(1):28-33.
27. Sibley SD, Lauck M, Bailey AL, et al. Discovery and characterization of distinct simian
pegiviruses in three wild African Old World monkey species. *PLoS One.*
2014;9(2):e98569.
28. Adams NJ, Prescott LE, Jarvis LM, et al. Detection in chimpanzees of a novel flavivirus
related to GB virus-C/hepatitis G virus. *J Gen Virol.* 1998;79 (Pt 8):1871-1877.
29. Baechlein C, Grundhoff A, Fischer N, et al. Pegivirus Infection in Domestic Pigs,
Germany. *Emerg Infect Dis.* 2016;22(7):1312-1314.
30. Yang C, Wang L, Shen H, et al. Detection and genetic characterization of porcine
pegivirus in pigs in the United States. *Transbound Emerg Dis.* 2018;65(3):618-626.
31. Lei D, Ye Y, Lin K, et al. Detection and genetic characterization of porcine pegivirus from
pigs in China. *Virus Genes.* 2019;55(2):248-252.
32. Epstein JH, Quan PL, Briese T, et al. Identification of GBV-D, a novel GB-like flavivirus
from old world frugivorous bats (Pteropus giganteus) in Bangladesh. *PLoS Pathog.*
2010;6:e1000972.
33. Kapoor A, Simmonds P, Scheel TK, et al. Identification of rodent homologs of hepatitis C
virus and pegiviruses. *mBio.* 2013;4(2):e00216-00213.
34. Shi M, Lin XD, Vasilakis N, et al. Divergent Viruses Discovered in Arthropods and
Vertebrates Revise the Evolutionary History of the Flaviviridae and Related Viruses. *J*
Virol. 2016;90(2):659-669.
35. Tomlinson JE, Kapoor A, Kumar A, et al. Viral testing of 18 consecutive cases of equine
serum hepatitis: A prospective study (2014-2018). *J Vet Intern Med.* 2019;33(1):251-
257.
36. Linnen J, Wages J, Jr., Zhang-Keck ZY, et al. Molecular cloning and disease association
of hepatitis G virus: a transfusion-transmissible agent. *Science.* 1996;271(5248):505-
508.
37. Wang JT, Tsai FC, Lee CZ, et al. A prospective study of transfusion-transmitted GB
virus C infection: similar frequency but different clinical presentation compared with
hepatitis C virus. *Blood.* 1996;88(5):1881-1886.
38. Nakao H, Okamoto H, Fukuda M, et al. Mutation rate of GB virus C/hepatitis G virus over
the entire genome and in subgenomic regions. *Virology.* 1997;233(1):43-50.
39. Theodore D, Lemon SM. GB virus C, hepatitis G virus, or human orphan flavivirus?
Hepatology. 1997;25(5):1285-1286.
40. Alter HJ. G-pers creepers, where'd you get those papers? A reassessment of the
literature on the hepatitis G virus. *Transfusion.* 1997;37(6):569-572.

41. Mohr EL, Murthy KK, McLinden JH, Xiang J, Stapleton JT. The natural history of non-
human GB virus C in captive chimpanzees. *J Gen Virol.* 2011;92(Pt 1):91-100.
42. Suzuki Y, Katayama K, Fukushi S, et al. Slow evolutionary rate of GB virus C/hepatitis G
virus. *J Mol Evol.* 1999;48(4):383-389.
43. Heringlake S, Tillmann HL, Cordes-Temme P, Trautwein C, Hunsmann G, Manns MP.
GBV-C/HGV is not the major cause of autoimmune hepatitis. *J Hepatol.* 1996;25(6):980-
984.
44. Bralet MP, Roudot-Thoraval F, Pawlotsky JM, et al. Histopathologic impact of GB virus C
infection on chronic hepatitis C. *Gastroenterology.* 1997;112(1):188-192.
45. Feucht HH, Fischer L, Sterneck M, Broelsch CE, Laufs R. GB virus C transmission by
blood products. *Lancet.* 1997;349(9049):435.
46. Goeser T, Seipp S, Wahl R, Muller HM, Stremmel W, Theilmann L. Clinical presentation
of GB-C virus infection in drug abusers with chronic hepatitis C. *J Hepatol.*
1997;26(3):498-502.
47. Kanda T, Yokosuka O, Imazeki F, et al. GB virus-C RNA in Japanese patients with
hepatocellular carcinoma and cirrhosis. *J Hepatol.* 1997;27(3):464-469.
48. Hadziyannis SJ. Fulminant hepatitis and the new G/GBV-C flavivirus. *J Viral Hepat.*
1998;5(1):15-19.
49. Rambusch EG, Wedemeyer H, Tillmann HL, Heringlake S, Manns MP. [Significance of
coinfection with hepatitis G virus for chronic hepatitis C--a review of the literature]. *Z
Gastroenterol.* 1998;36(1):41-53.
50. Brown KE, Wong S, Young NS. Prevalence of GBV-C/HGV, a novel 'hepatitis' virus, in
patients with aplastic anaemia. *Br J Haematol.* 1997;97(2):492-496.
51. Servant A, Bogard M, Delaugerre C, Cohen P, Deny P, Guillevin L. GB virus C in
systemic medium- and small-vessel necrotizing vasculitides. *Br J Rheumatol.*
1998;37(12):1292-1294.
52. Viazov S, Alberts KR, Ross RS, Seemayer CA, Roggendorf M. Lack of association
between GBV-C infection and spontaneous abortion. *Eur J Clin Microbiol Infect Dis.*
1999;18(6):458-459.
53. Misiani R, Mantero G, Bellavita P, et al. GB virus C infection in patients with type II
mixed cryoglobulinemia. *Ann Intern Med.* 1997;127(10):891-894.
54. Crovatto M, Mazzaro C, Mishiro S, et al. GBV-C/HGV and HCV infection in mixed
cryoglobulinaemia. *Br J Haematol.* 1999;106(2):510-514.
55. Liu F, Knight GB, Agnello V. Hepatitis C virus but not GB virus C/hepatitis G virus has a
role in type II cryoglobulinemia. *Arthritis Rheum.* 1999;42(9):1898-1901.
56. Hardie D, Smuts H. Human pegivirus-1 in the CSF of patients with HIV-associated
neurocognitive disorder (HAND) may be derived from blood in highly viraemic patients. *J
Clin Virol.* 2017;91:58-61.
57. Sauleda S, Rio J, Montalban X, Martinez-Caceres E, Esteban JI, Guardia J. Lack of
association between hepatitis G virus and multiple sclerosis. *J Neurol Neurosurg
Psychiatry.* 1998;64(2):283.
58. Lamoril J, Andant C, Bogard C, et al. Epidemiology of hepatitis C and G in sporadic and
familial porphyria cutanea tarda. *Hepatology.* 1998;27(3):848-852.
59. Font J, Tassies D, Garcia-Carrasco M, et al. Hepatitis G virus infection in primary
Sjogren's syndrome: analysis in a series of 100 patients. *Ann Rheum Dis.*
1998;57(1):42-44.
60. Jones JF, Kulkarni PS, Butera ST, Reeves WC. GB virus-C--a virus without a disease:
we cannot give it chronic fatigue syndrome. *BMC Infect Dis.* 2005;5:78.
61. de Souza AJS, Malheiros AP, de Sousa ERP, et al. First report of equine Pegivirus in
South America, Brazil. *Acta Trop.* 2015;152:56-59.

62.   Chandriani S, Skewes-Cox P, Zhong W, et al. Identification of a previously undescribed
608   divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis.
609   *Proc Natl Acad Sci U S A.* 2013;110(15):E1407-1415.
610   63.   Tomlinson JE, Tennant BC, Struzyna A, et al. Viral testing of 10 cases of Theiler's
611   disease and 37 in-contact horses in the absence of equine biologic product
612   administration: A prospective study (2014-2018). *J Vet Intern Med.* 2019;33(1):258-265.
613   64.   Tucker TJ, Smuts HE, Eedes C, et al. Evidence that the GBV-C/hepatitis G virus is
614   primarily a lymphotropic virus. *J Med Virol.* 2000;61(1):52-58.
615   65.   Radkowski M, Kubicka J, Kisiel E, et al. Detection of active hepatitis C virus and
616   hepatitis G virus/GB virus C replication in bone marrow in human subjects. *Blood.*
617   2000;95(12):3986-3989.
618   66.   George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B
619   lymphocytes. *J Infect Dis.* 2006;193(3):451-454.
620   67.   Kisiel E, Cortez KC, Pawelczyk A, et al. Hepatitis G virus/GBV-C in serum, peripheral
621   blood mononuclear cells and bone marrow in patients with hematological malignancies.
622   *Infect Genet Evol.* 2013;19:195-199.
623   68.   Stapleton JT, Chaloner K, Zhang J, et al. GBV-C viremia is associated with reduced
624   CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.
625   *AIDS.* 2009;23(5):605-610.
626   69.   Maidana-Giret MT, Silva TM, Sauer MM, et al. GB virus type C infection modulates T-
627   cell activation independently of HIV-1 viral load. *AIDS.* 2009;23(17):2277-2287.
628   70.   Berzsenyi MD, Woollard DJ, McLean CA, et al. Down-regulation of intra-hepatic T-cell
629   signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver
630   disease. *J Hepatol.* 2011;55(3):536-544.
631   71.   Rydze RT, Xiang J, McLinden JH, Stapleton JT. GB virus type C infection polarizes T-
632   cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein
633   expression. *J Infect Dis.* 2012;206(1):69-72.
634   72.   Rydze RT, Bhattarai N, Stapleton JT. GB virus C infection is associated with a reduced
635   rate of reactivation of latent HIV and protection against activation-induced T-cell death.
636   *Antivir Ther.* 2012;17(7):1271-1279.
637   73.   Stapleton JT, Xiang J, McLinden JH, et al. A novel T cell evasion mechanism in
638   persistent RNA virus infection. *Trans Am Clin Climatol Assoc.* 2014;125:14-24;
639   discussion 24-16.
640   74.   Bhattarai N, Stapleton JT. GB virus C: the good boy virus? *Trends Microbiol.*
641   2012;20(3):124-130.
642   75.   Xiang J, McLinden JH, Rydze RA, et al. Viruses within the Flaviviridae decrease CD4
643   expression and inhibit HIV replication in human CD4+ cells. *J Immunol.*
644   2009;183(12):7860-7869.
645   76.   Bhattarai N, Rydze RT, Chivero ET, Stapleton JT. GB virus C viremia is associated with
646   higher levels of double-negative T cells and lower T-cell activation in HIV-infected
647   individuals receiving antiretroviral therapy. *J Infect Dis.* 2012;206(9):1469-1472.
648   77.   Quan PL, Firth C, Conte JM, et al. Bats are a major natural reservoir for hepaciviruses
649   and pegiviruses. *Proc Natl Acad Sci U S A.* 2013;110(20):8194-8199.
650   78.   Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus
651   type 1 genomes from subtype C-infected seroconverters in India, with evidence of
652   intersubtype recombination. *J Virol.* 1999;73(1):152-160.
653   79.   Virus Taxonomy: 2019 Release: Genus: Pegivirus. 2020. https://talk.ictvonline.org/ictv-
654   reports/ictv_online_report/positive-sense-rna-viruses/w/flaviviridae/363/genus-pegivirus.
655   Accessed 04 April 2020.

80. Rodrigues TCS, Subramaniam K, McCulloch SD, et al. Genomic characterization of a
novel pegivirus species from free-ranging bottlenose dolphins (Tursiops truncatus) in the
Indian River Lagoon, Florida. *Virus Res.* 2019;263:98-101.
81. Smith DB, Becher P, Bukh J, et al. Proposed update to the taxonomy of the genera
Hepacivirus and Pegivirus within the Flaviviridae family. *J Gen Virol.* 2016;97(11):2894-
2907.
82. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences
associated with human hepatitis. *Nat Med.* 1995;1(6):564-569.
83. Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review
and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus
within the family Flaviviridae. *J Gen Virol.* 2011;92(Pt 2):233-246.
84. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus C/hepatitis
G virus coinfection on the course of HIV infection in hemophilia patients in Japan. *J
Acquir Immune Defic Syndr Hum Retrovirol.* 1998;17(3):209-213.
85. Tillmann HL, Heringlake S, Trautwein C, et al. Antibodies against the GB virus C
envelope 2 protein before liver transplantation protect against GB virus C de novo
infection. *Hepatology.* 1998;28(2):379-384.
86. Lefrere JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis
G virus RNA is associated with a slower immunologic, virologic, and clinical progression
of human immunodeficiency virus disease in coinfected persons. *J Infect Dis.*
1999;179(4):783-789.
87. Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G
virus infection on progression of HIV infection in patients with hemophilia. Multicenter
Hemophilia Cohort Study. *Ann Intern Med.* 2000;132(12):959-963.
88. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on
survival among patients with HIV infection. *N Engl J Med.* 2001;345(10):707-714.
89. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced
mortality among HIV-infected patients. *N Engl J Med.* 2001;345(10):715-724.
90. Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and
survival in HIV-infected men. *N Engl J Med.* 2004;350(10):981-990.
91. Van der Bij AK, Kloosterboer N, Prins M, et al. GB virus C coinfection and HIV-1 disease
progression: The Amsterdam Cohort Study. *J Infect Dis.* 2005;191(5):678-685.
92. Tenckhoff S, Kaiser T, Bredeek F, et al. Role of GB virus C in HIV-1-infected and
hepatitis C virus-infected hemophiliac children and adolescents. *J Acquir Immune Defic
Syndr.* 2012;61(2):243-248.
93. Sahni H, Kirkwood K, Kyriakides TC, et al. GBV-C viremia and clinical events in
advanced HIV infection. *J Med Virol.* 2014;86(3):426-432.
94. Hollingsworth RC, Jameson CL, Minton JE, et al. GBV-C/HGV coinfection in HIV-1-
positive men: frequent detection of viral RNA in blood plasma but absence from seminal
fluid plasma. *J Med Virol.* 1998;56(4):321-326.
95. Goubau P, Liu HF, Goderniaux E, Burtonboy G. Influence of CD4+ lymphocyte counts
on GB virus C/hepatitis G virus carriership in HIV-positive individuals. *J Med Virol.*
1999;57(4):367-369.
96. Rey D, Vidinic-Moularde J, Meyer P, et al. High prevalence of GB virus C/hepatitis G
virus RNA and antibodies in patients infected with human immunodeficiency virus type 1.
Eur J Clin Microbiol Infect Dis. 2000;19(9):721-724.
97. Voirin N, Trepo C, Esteve J, et al. Effects of co-infection with hepatitis C virus and GB
virus C on CD4 cell count and HIV-RNA level among HIV-infected patients treated with
highly active antiretroviral therapy. *AIDS.* 2002;16(11):1556-1559.
98. Li C, Collini P, Danso K, et al. GB virus C and HIV-1 RNA load in single virus and co-
infected West African individuals. *AIDS.* 2006;20(3):379-386.

99. Lauck M, Bailey AL, Andersen KG, Goldberg TL, Sabeti PC, O'Connor DH. GB virus C
coinfections in west African Ebola patients. *J Virol.* 2015;89(4):2425-2429.
100. Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late
GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. *HIV Med.*
2006;7(3):173-180.
101. Stapleton JT, Martinson JA, Klinzman D, Xiang J, Desai SN, Landay A. GB virus C
infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected
individuals. *AIDS.* 2013;27(11):1829-1832.
102. De Renzo A, Persico E, de Marino F, et al. High prevalence of hepatitis G virus infection
in Hodgkin's disease and B-cell lymphoproliferative disorders: absence of correlation
with hepatitis C virus infection. *Haematologica.* 2002;87(7):714-718; discussion 718.
103. Krajden M, Yu A, Braybrook H, et al. GBV-C/hepatitis G virus infection and non-Hodgkin
lymphoma: a case control study. *Int J Cancer.* 2010;126(12):2885-2892.
104. Giannoulis E, Economopoulos T, Mandraveli K, et al. The prevalence of hepatitis C and
hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a
Hellenic Cooperative Oncology Group Study. *Acta Haematol.* 2004;112(4):189-193.
105. Wiwanitkit V. Individuals with HGV-RNA are at high risk of B cell non-Hodgkin's
lymphoma development. *Asian Pac J Cancer Prev.* 2005;6(2):215-216.
106. Ellenrieder V, Weidenbach H, Frickhofen N, et al. HCV and HGV in B-cell non-Hodgkin's
lymphoma. *J Hepatol.* 1998;28(1):34-39.
107. Pavlova BG, Heinz R, Selim U, Tuchler H, Pittermann E, Eder G. Association of GB
virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different
malignant potential. *J Med Virol.* 1999;57(4):361-366.
108. Chang CM, Stapleton JT, Klinzman D, et al. GBV-C infection and risk of NHL among
U.S. adults. *Cancer Res.* 2014;74(19):5553-5560.
109. Fama A, Xiang J, Link BK, et al. Human Pegivirus infection and lymphoma risk and
prognosis: a North American study. *Br J Haematol.* 2018;182(5):644-653.
110. Fama A, Larson MC, Link BK, et al. Human Pegivirus Infection and Lymphoma Risk: A
Systematic Review and Meta-analysis. *Clin Infect Dis.* 2019.
111. Collier JD, Zanke B, Moore M, et al. No association between hepatitis C and B-cell
lymphoma. *Hepatology.* 1999;29(4):1259-1261.
112. Arican A, Sengezer T, Bozdayi M, et al. Prevalence of hepatitis-G virus and hepatitis-C
virus infection in patients with non-Hodgkin's lymphoma. *Med Oncol.* 2000;17(2):123-
126.
113. Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, et al. Hepatitis C virus and GBV-C
virus prevalence among patients with B-cell lymphoma in different European regions: a
case-control study of the International Extranodal Lymphoma Study Group. *Hematol*
Oncol. 2012;30(3):137-142.
114. Keresztes K, Takacs M, Horanyi M, Miltenyi Z, Illes A. HCV and HGV infection in
Hodgkin's disease. *Pathol Oncol Res.* 2003;9(4):222-225.
115. Persico M, De Renzo A, Persico E, Notaro R, Torella R, Rotoli B. Hepatitis G virus in
patients with Hodgkin's lymphoma. *Br J Haematol.* 1998;103(4):1206-1207.
116. Reshetnyak VI, Sharafanova TI, Il'chenko LY, Poroshenko GG. DNA structure in
peripheral blood lymphocytes from patients with chronic viral liver damages. *Bull Exp*
Biol Med. 2002;133(4):399-400.
117. Porter AF, Pettersson JH-O, Wei-Shan C, et al. Metagenomic identification of diverse
animal hepaciviruses and pegiviruses. *bioRxiv.* 2020.
118. Bukh J, Apgar CL. Five new or recently discovered (GBV-A) virus species are
indigenous to New World monkeys and may constitute a separate genus of the
Flaviviridae. *Virology.* 1997;229(2):429-436.

119.   Seifried E, Bialleck H, Weber H, et al. [Prevalence of hepatitis G virus genome in blood
758   donors]. *Beitr Infusionsther Transfusionsmed.* 1997;34:11-15.

759   120.   Roth WK, Waschk D, Marx S, et al. Prevalence of hepatitis G virus and its strain variant,
760   the GB agent, in blood donations and their transmission to recipients. *Transfusion.*
761   1997;37(6):651-656.

762   121.   Yoshikawa A, Fukuda S, Itoh K, et al. Infection with hepatitis G virus and its strain
763   variant, the GB agent (GBV-C), among blood donors in Japan. *Transfusion.*
764   1997;37(6):657-663.

765   122.   Gutierrez RA, Dawson GJ, Knigge MF, et al. Seroprevalence of GB virus C and
766   persistence of RNA and antibody. *J Med Virol.* 1997;53(2):167-173.

767   123.   Lara C, Halasz R, Sonnerborg A, Sallberg M. Detection of hepatitis G virus RNA in
768   persons with and without known risk factors for blood-borne viral infections in Sweden
769   and Honduras. *J Clin Microbiol.* 1998;36(1):255-257.

770   124.   Gallian P, Rodrigues V, Cantaloube JF, et al. High prevalence of GB-C/hepatitis G virus
771   in a Brazilian population with helminth infection. *J Med Virol.* 1998;56(4):310-315.

772   125.   Mphahlele MJ, Aspinall S, Spooner R, Carman WF. Age related prevalence of hepatitis
773   G virus in South Africans. *J Clin Pathol.* 1999;52(10):752-757.

774   126.   Corwin AL, Hyams KC, Kim JP, et al. Short report: evidence of worldwide transmission
775   of hepatitis G virus. *Am J Trop Med Hyg.* 1997;57(4):455-456.

776   127.   Herrera S, Perlaza BL, Bonelo A, Arevalo-Herrera M. Aotus monkeys: their great value
777   for anti-malaria vaccines and drug testing. *Int J Parasitol.* 2002;32(13):1625-1635.

778   128.   Hutt MS, Davies DR, Voller A. Malarial infections in Aotus trivirgatus with special
779   reference to renal pathology. II. P. falciparum and mixed malaria infections. *Br J Exp
780   Pathol.* 1975;56(5):429-438.

781   129.   Schmidt LH. Plasmodium falciparum and Plasmodium vivax infections in the owl monkey
782   (Aotus trivirgatus). II. Responses to chloroquine, quinine, and pyrimethamine. *Am J Trop
783   Med Hyg.* 1978;27(4):703-717.

784   130.   Karayiannis P, Thomas HC. Current status of hepatitis G virus (GBV-C) in transfusion: is
785   it relevant? *Vox Sang.* 1997;73(2):63-69.

786   131.   Stark K, Meyer CG, Tacke M, et al. Hepatitis G virus RNA and hepatitis G virus
787   antibodies in renal transplant recipients: prevalence and risk factors. *Transplantation.*
788   1997;64(4):608-612.

789   132.   Kallinowski B, Ahmadi R, Seipp S, Bommer J, Stremmel W. Clinical impact of GB-C
790   virus in haemodialysis patients. *Nephrol Dial Transplant.* 1998;13(1):93-98.

791   133.   Huang CH, Kao JH, Kuo YM, Tsai TJ, Hung KY, Chen DS. GB virus C/hepatitis G virus
792   infection in patients on continuous ambulatory peritoneal dialysis. *Nephrol Dial
793   Transplant.* 1998;13(11):2914-2919.

794   134.   Fiordalisi G, Bettinardi A, Zanella I, et al. Parenteral and sexual transmission of GB virus
795   C and hepatitis C virus among human immunodeficiency virus-positive patients. *J Infect
796   Dis.* 1997;175(4):1025-1026.

797   135.   Anastassopoulou CG, Paraskevis D, Sypsa V, et al. Prevalence patterns and genotypes
798   of GB virus C/hepatitis G virus among imprisoned intravenous drug users. *J Med Virol.*
799   1998;56(3):246-252.

800   136.   Shibuya A, Takeuchi A, Sakurai K, Saigenji K. Hepatitis G virus infection from needle-
801   stick injuries in hospital employees. *J Hosp Infect.* 1998;40(4):287-290.

802   137.   Kao JH, Chen W, Chen PJ, Lai MY, Lin RY, Chen DS. GB virus-C/hepatitis G virus
803   infection in prostitutes: possible role of sexual transmission. *J Med Virol.* 1997;52(4):381-
804   384.

805   138.   Semprini AE, Persico T, Thiers V, et al. Absence of hepatitis C virus and detection of
806   hepatitis G virus/GB virus C RNA sequences in the semen of infected men. *J Infect Dis.*
807   1998;177(4):848-854.

139. Viazov S, Riffelmann M, Sarr S, Ballauff A, Meisel H, Roggendorf M. Transmission of
GBV-C/HGV from drug-addicted mothers to their babies. *J Hepatol.* 1997;27(1):85-90.
140. Zanetti AR, Tanzi E, Romano L, et al. Multicenter trial on mother-to-infant transmission
of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses
Transmission. *J Med Virol.* 1998;54(2):107-112.
141. Hino K, Moriya T, Ohno N, et al. Mother-to-infant transmission occurs more frequently
with GB virus C than hepatitis C virus. *Arch Virol.* 1998;143(1):65-72.
142. Lin HH, Kao JH, Yeh KY, et al. Mother-to-infant transmission of GB virus C/hepatitis G
virus: the role of high-titered maternal viremia and mode of delivery. *J Infect Dis.*
1998;177(5):1202-1206.
143. Santos LM, Lobato RC, Barral MFM, Goncalves CV, da Hora VP, Martinez AMB.
Prevalence and vertical transmission of human pegivirus among pregnant women
infected with HIV. *Int J Gynaecol Obstet.* 2017;138(1):113-118.
144. Prati D, Zanella A, Bosoni P, et al. The incidence and natural course of transfusion-
associated GB virus C/hepatitis G virus infection in a cohort of thalassemic patients. The
Cooleycare Cooperative Group. *Blood.* 1998;91(3):774-777.
145. Lauck M, Sibley SD, Hyeroba D, et al. Exceptional simian hemorrhagic fever virus
diversity in a wild African primate community. *J Virol.* 2013;87(1):688-691.
146. Lauck M, Switzer WM, Sibley SD, et al. Discovery and full genome characterization of
two highly divergent simian immunodeficiency viruses infecting black-and-white colobus
monkeys (Colobus guereza) in Kibale National Park, Uganda. *Retrovirology.*
2013;10:107.
147. Gartner LP, Hiatt JL. *Color atlas of histology.* 5th ed. Philadelphia: Wolters Kluwer
Health/Lippincott William & Wilkins; 2009.
832